Login
About Alexion
Our Leadership
Our Partnerships
Our Ethical Standards
Our History
Patient Focus
Advocacy
Patient Stories
Products
Soliris
®
PNH
aHUS
Strensiq
®
Kanuma
®
Research & Development
Our Pipeline
Development Programs
Investigator-Sponsored Research
Discovery Partnerships
Responsibility
Global Access to Medicines Policy
Main Menu
Careers
Job Opportunities
Why Choose Alexion
Culture
Compensation & Benefits
Work/Life Balance
Health & Wellness
Financial Security
Recognition & Rewards
Personal Growth & Development
Professional Development
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Select a Country
Investors
News
Contact
Search for:
North America
Canada
United States
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
United Kingdom
Asia Pacific
Australia
China
India
Japan
About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Home
»
Newsroom
»
Press Releases
»
Product News
Product News
Press Releases
Filter by Category
All Press Releases
Company Releases
Company Statements
Financial Releases
Product Releases
Sort by Year
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Media
Inquiries
Media
Materials
Email
Alerts
Search Newsroom
Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® (Eculizumab) as a Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)
January 9, 2017
HTML
PDF
Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris®) for the Prevention of Delayed Graft Function (DGF) After Kidney Transplantation
December 21, 2016
HTML
PDF
New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris® (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant
November 17, 2016
HTML
PDF
New Long-Term Data Presented at AASLD Show Reduction in Liver Fibrosis and Cirrhosis in a Cohort of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebelipase alfa)
November 11, 2016
HTML
PDF
Researchers to Present New Phase 1/2 Data on ALXN1210 in Patients with PNH at ASH 2016 Annual Meeting
November 3, 2016
HTML
PDF
Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
October 27, 2016
HTML
PDF
FDA Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
October 19, 2016
HTML
PDF
New Long-Term Data Presented at WCPGHAN 2016 Show Rapid and Sustained Improvements in Important Markers of Liver Injury and Lipid Abnormalities in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebelipase alfa)
October 6, 2016
HTML
PDF
European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
August 29, 2016
HTML
PDF
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB)
July 14, 2016
HTML
PDF
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
